Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir

C. Ippoliti, A. Morgan, D. Warkentin, K. Van Besien, R. Mehra, I. Khouri, S. Giralt, J. Gajewski, R. Champlin, B. Andersson, D. Przepiorka

    Research output: Contribution to journalArticle

    19 Scopus citations

    Abstract

    Cytomegalovirus (CMV) disease can be prevented by administration of ganciclovir prophylactically post-transplant. However, up to 30% of patients discontinue use of ganciclovir as a result of profound neutropenia and may subsequently develop CMV infections while unprotected. To prevent reactivation of CMV, we administered foscarnet to 39 adults unable to receive ganciclovir due to delayed engraftment or ganciclovir-induced neutropenia. Twenty-four (62%) of the patients had received T cell-depleted marrow transplants. Foscarnet sodium 60 mg/kg i.v. daily was continued until the neutropenia resolved, at which time ganciclovir was resumed. CMV prophylaxis commenced at a median of 28 days following transplantation. Median time to initiation of foscarnet was day 60 post-transplant, and the median duration of treatment was 22 days. Foscarnet was well-tolerated. Six (15%) patients had CMV detected while receiving prophylaxis, and CMV-related mortality was 5%. Foscarnet is a safe and effective agent for prevention of CMV disease in allogeneic transplant recipients unable to receive ganciclovir.

    Original languageEnglish (US)
    Pages (from-to)491-495
    Number of pages5
    JournalBone marrow transplantation
    Volume20
    Issue number6
    DOIs
    StatePublished - Sep 2 1997

      Fingerprint

    Keywords

    • Allogeneic
    • BMT
    • Cytomegalovirus
    • Foscarnet
    • Ganciclovir

    ASJC Scopus subject areas

    • Hematology
    • Transplantation

    Cite this

    Ippoliti, C., Morgan, A., Warkentin, D., Van Besien, K., Mehra, R., Khouri, I., Giralt, S., Gajewski, J., Champlin, R., Andersson, B., & Przepiorka, D. (1997). Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. Bone marrow transplantation, 20(6), 491-495. https://doi.org/10.1038/sj.bmt.1700910